N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
Our lead programme, N4 101, is a dual-targeting, orally delivered RNA therapeutic designed to improve the lives of patients with inflammatory bowel disease.
Watch our video animation below to see Nuvec® in action:
Latest news and updates
New corporate presentation – October 2024
Our new corporate presentation is now available to download. Listen to the video update from CEO, Nigel Theobald here. Key points covered in the presentation include:N4 Pharma's strategic focus on two key lead programs: N4 101 [...]
Roundtable: What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?
Pharma’s Almanac’s Q2 2024 roundtable ‘What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?’ features a response from Nigel Theobald, CEO, N4 Pharma.Contributing to the discussion, [...]
Article: Are oral formulations of oligonucleotide therapeutics within reach?
Our latest article explores the challenges with targeting the gastrointestinal (GI) tract and outlines the current strategies aiming to unlock the potential of oral delivery for siRNA drugs targeted against GI diseases and cancers. We [...]